A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Recruiting

Phase 1

ALLO-329A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Sponsor:

Allogene Therapeutics

Code:

NCT07085104

Conditions

Systemic Lupus Erythematosus (With and Without Nephritis)

Idiopathic Inflammatory Myopathy

Systemic Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 69

Healthy Volunteers: Not accepted

Interventions

ALLO-329

Cyclophophamide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-12. This information was provided to ClinicalTrials.gov by Allogene Therapeutics on 2026-02-04.